As such, today’s pharmaceutical manufacturers are navigating a rapidly evolving landscape.
A stronger focus on patient-centric healthcare is driving demand for dosage forms that are easier to administer and support patient compliance.
From smaller tablets to more acceptable liquid and chewable formulations, excipients play an increasingly strategic role.
Beyond enabling product performance, they help manufacturers to improve supply chain reliability, simplify production, support regulatory compliance and enhance the patient experience.
“As preventive health and self-care continue to grow, excipients will play an increasingly important role in pharma. That’s why Cargill is investing for the long-term,” notes Eelco van Oosterbosch, Health & Nutrition Marketing Director at Cargill.
But success here depends on more than just sourcing the right ingredients. It requires a partner who can simplify complexity, reduce risk and enable consistent, scalable performance — from development through to commercialisation.
Cargill is much more than a supplier of excipients. “We’re bringing together portfolio breadth, regulatory strength and reliable supply to support customers throughout the product development journey,” Eelco adds.
Manage risk and achieve reliable performance
As regulatory expectations rise, supply chains become more vulnerable and manufacturers seek greater efficiency and patient-centricity, excipients are playing an even more strategic role.
Cargill’s approach is built around helping customers to reduce complexity, manage risk and achieve reliable performance throughout the product lifecycle.
“In pharma, innovation matters … but reliability matters more. Customers need to know that their excipients will be available not just today, but decades from now,” notes Sergio Neves, Innovation Collaboration and Partnerships Adviser at Cargill.
Catherine Boghmans, Senior Application Specialist, Specialised Nutrition, further notes how every dosage form has different requirements.
“Our strength lies in both understanding how excipients perform and helping customers to achieve the right balance in their formulation.”
But as Paula Garcia, Senior Director of R&D, Health & Nutrition, stresses, Cargill’s role is not to replace formulation teams; it’s to enable them.
“Through consistent quality, supply security and ingredient expertise, we help to simplify complexity,” she notes.
In pharma, consistency isn’t a goal; it’s a requirement.
“Our focus is delivering reproducible, audit-ready quality, batch after batch,” notes Geertrui Haest, Senior Scientific & Regulatory Affairs Specialist.
Reliable supply, technical expertise, practical innovation
Manufacturers are increasingly looking for partners who can provide more than high-quality excipients.
They need trusted collaborators who combine dependable supply, technical expertise, regulatory understanding and a broad portfolio to help reduce complexity and support success from development through to commercialisation.
That’s why they rely on Cargill for “exceptional excipients, enabled by expertise.”
At CPHI 2026, visitors to stand #1G10 will discover why Cargill is the trusted long-term formulation partner for pharmaceutical manufacturers.
Drawing on more than 40 years of excipient experience, Cargill combines portfolio breadth, technical expertise, regulatory know-how and supply chain strength to help customers navigate an increasingly complex pharmaceutical landscape.
